Press Releases

Apr 4, 2023 7:00 am EDT KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

Jan 18, 2023 11:50 am EST Kazia Therapeutics CEO talks $4.5 million capital raise

Jan 16, 2023 7:01 am EST KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

Dec 15, 2022 7:01 am EST KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

Dec 12, 2022 7:01 am EST KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Dec 6, 2022 11:45 am EST Kazia Therapeutics talks positive pre-clinical data for EVT801

Dec 1, 2022 7:01 am EST COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL

Nov 9, 2022 7:00 am EST KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Oct 27, 2022 7:00 am EDT KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA

Oct 6, 2022 8:00 am EDT PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY